Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiotherapy Planning, Computer-Assisted | 118 | 2024 | 1658 | 11.450 |
Why?
|
Radiotherapy, Intensity-Modulated | 36 | 2024 | 799 | 5.630 |
Why?
|
Radiotherapy Dosage | 97 | 2024 | 2893 | 3.810 |
Why?
|
Radiotherapy, Conformal | 31 | 2011 | 547 | 3.790 |
Why?
|
Radiometry | 29 | 2013 | 816 | 3.320 |
Why?
|
Radiation Oncology | 11 | 2022 | 554 | 2.060 |
Why?
|
Radiotherapy | 17 | 2023 | 1504 | 1.950 |
Why?
|
Phantoms, Imaging | 34 | 2024 | 2469 | 1.730 |
Why?
|
Algorithms | 60 | 2023 | 13796 | 1.680 |
Why?
|
Radiation Pneumonitis | 2 | 2022 | 104 | 1.360 |
Why?
|
Radiotherapy, Computer-Assisted | 8 | 2011 | 91 | 1.310 |
Why?
|
Protons | 16 | 2023 | 1116 | 1.260 |
Why?
|
Radiotherapy, High-Energy | 11 | 2009 | 224 | 1.230 |
Why?
|
Neoplasms | 29 | 2023 | 21688 | 1.160 |
Why?
|
Brain Neoplasms | 13 | 2024 | 8832 | 0.960 |
Why?
|
Models, Biological | 21 | 2019 | 9443 | 0.950 |
Why?
|
Models, Theoretical | 18 | 2021 | 3548 | 0.930 |
Why?
|
Positron-Emission Tomography | 17 | 2020 | 6420 | 0.930 |
Why?
|
Radiation Injuries | 7 | 2024 | 1175 | 0.920 |
Why?
|
Scattering, Radiation | 14 | 2016 | 491 | 0.900 |
Why?
|
Photons | 18 | 2018 | 584 | 0.870 |
Why?
|
Chordoma | 5 | 2023 | 348 | 0.870 |
Why?
|
Motion | 10 | 2012 | 781 | 0.860 |
Why?
|
Liver Neoplasms | 8 | 2021 | 4248 | 0.790 |
Why?
|
Muscle Fibers, Skeletal | 2 | 2024 | 544 | 0.780 |
Why?
|
Monte Carlo Method | 20 | 2024 | 1266 | 0.750 |
Why?
|
Organs at Risk | 5 | 2022 | 361 | 0.740 |
Why?
|
Uncertainty | 8 | 2022 | 740 | 0.730 |
Why?
|
Lung Neoplasms | 18 | 2024 | 13196 | 0.690 |
Why?
|
Four-Dimensional Computed Tomography | 2 | 2011 | 147 | 0.690 |
Why?
|
Glioblastoma | 4 | 2023 | 3453 | 0.660 |
Why?
|
Physics | 5 | 2021 | 93 | 0.630 |
Why?
|
Health Physics | 4 | 2022 | 28 | 0.610 |
Why?
|
Tomography, X-Ray Computed | 27 | 2024 | 20142 | 0.590 |
Why?
|
Glioma | 3 | 2024 | 3373 | 0.570 |
Why?
|
Tumor Burden | 4 | 2022 | 1883 | 0.570 |
Why?
|
Head and Neck Neoplasms | 16 | 2024 | 2829 | 0.570 |
Why?
|
Radiation Dosage | 7 | 2018 | 1952 | 0.550 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 7 | 2024 | 5282 | 0.510 |
Why?
|
Movement | 10 | 2015 | 1464 | 0.510 |
Why?
|
Spinal Neoplasms | 6 | 2013 | 712 | 0.510 |
Why?
|
Probability | 8 | 2022 | 2468 | 0.500 |
Why?
|
Dose-Response Relationship, Radiation | 13 | 2011 | 871 | 0.500 |
Why?
|
Technology, Radiologic | 4 | 2013 | 160 | 0.490 |
Why?
|
Humans | 151 | 2024 | 746044 | 0.440 |
Why?
|
Particle Accelerators | 10 | 2021 | 171 | 0.440 |
Why?
|
Lung Injury | 1 | 2018 | 424 | 0.430 |
Why?
|
Computer Simulation | 14 | 2012 | 6146 | 0.410 |
Why?
|
Image Processing, Computer-Assisted | 16 | 2024 | 8901 | 0.390 |
Why?
|
Mathematics | 6 | 2019 | 716 | 0.390 |
Why?
|
Gadolinium DTPA | 1 | 2014 | 824 | 0.380 |
Why?
|
Biomedical Technology | 1 | 2013 | 211 | 0.370 |
Why?
|
Software | 8 | 2012 | 4399 | 0.350 |
Why?
|
Image Interpretation, Computer-Assisted | 3 | 2007 | 3306 | 0.340 |
Why?
|
Relative Biological Effectiveness | 10 | 2018 | 321 | 0.340 |
Why?
|
Diffusion of Innovation | 1 | 2013 | 710 | 0.310 |
Why?
|
Reproducibility of Results | 26 | 2022 | 19804 | 0.310 |
Why?
|
Database Management Systems | 1 | 2009 | 264 | 0.300 |
Why?
|
Hepatocytes | 1 | 2014 | 1209 | 0.290 |
Why?
|
Biophysical Phenomena | 9 | 2003 | 321 | 0.280 |
Why?
|
Prostatic Neoplasms | 16 | 2022 | 11216 | 0.280 |
Why?
|
Electrons | 3 | 2008 | 260 | 0.280 |
Why?
|
Body Burden | 8 | 2009 | 158 | 0.280 |
Why?
|
Models, Statistical | 13 | 2022 | 5027 | 0.280 |
Why?
|
Biophysics | 9 | 2003 | 382 | 0.270 |
Why?
|
Quality Assurance, Health Care | 2 | 2016 | 2162 | 0.270 |
Why?
|
Therapy, Computer-Assisted | 1 | 2008 | 268 | 0.270 |
Why?
|
Synchrotrons | 3 | 2017 | 38 | 0.270 |
Why?
|
Sensitivity and Specificity | 18 | 2009 | 14537 | 0.270 |
Why?
|
Respiratory Mechanics | 2 | 2008 | 680 | 0.250 |
Why?
|
Cerebellar Neoplasms | 1 | 2010 | 584 | 0.250 |
Why?
|
Respiration | 6 | 2010 | 1644 | 0.250 |
Why?
|
Visible Human Projects | 1 | 2024 | 12 | 0.240 |
Why?
|
Medulloblastoma | 1 | 2010 | 675 | 0.240 |
Why?
|
Calibration | 6 | 2023 | 800 | 0.240 |
Why?
|
Normal Distribution | 5 | 2012 | 272 | 0.230 |
Why?
|
Spine | 1 | 2010 | 1092 | 0.220 |
Why?
|
Pancreatic Neoplasms | 3 | 2011 | 5261 | 0.220 |
Why?
|
Diffusion Tensor Imaging | 2 | 2024 | 2348 | 0.210 |
Why?
|
Linear Models | 2 | 2018 | 5821 | 0.210 |
Why?
|
Linear Energy Transfer | 1 | 2003 | 157 | 0.210 |
Why?
|
Sarcoma | 2 | 2022 | 1793 | 0.200 |
Why?
|
Technology Assessment, Biomedical | 1 | 2004 | 308 | 0.200 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2022 | 1996 | 0.200 |
Why?
|
Feasibility Studies | 7 | 2022 | 5092 | 0.190 |
Why?
|
Anisotropy | 1 | 2024 | 1272 | 0.180 |
Why?
|
Time Factors | 15 | 2018 | 39587 | 0.180 |
Why?
|
Prostheses and Implants | 1 | 2007 | 1270 | 0.170 |
Why?
|
Bone Marrow | 1 | 2010 | 2901 | 0.170 |
Why?
|
Magnetic Resonance Imaging | 10 | 2023 | 35784 | 0.170 |
Why?
|
X-Ray Therapy | 1 | 1999 | 8 | 0.170 |
Why?
|
Skull Neoplasms | 2 | 2013 | 172 | 0.170 |
Why?
|
Entrepreneurship | 1 | 2019 | 23 | 0.170 |
Why?
|
Spectrometry, Gamma | 1 | 2018 | 5 | 0.160 |
Why?
|
Lymphocyte Count | 1 | 2021 | 775 | 0.160 |
Why?
|
Muscles | 1 | 2023 | 1583 | 0.160 |
Why?
|
Skull Base Neoplasms | 1 | 2021 | 269 | 0.150 |
Why?
|
Radiobiology | 1 | 2018 | 91 | 0.150 |
Why?
|
Radiation Protection | 4 | 2013 | 426 | 0.140 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2004 | 1181 | 0.140 |
Why?
|
Databases, Factual | 2 | 2009 | 7810 | 0.140 |
Why?
|
Subtraction Technique | 3 | 2009 | 519 | 0.130 |
Why?
|
Organizational Innovation | 1 | 2019 | 533 | 0.130 |
Why?
|
Patient Positioning | 2 | 2015 | 322 | 0.130 |
Why?
|
Markov Chains | 1 | 2019 | 958 | 0.130 |
Why?
|
Oxygen Radioisotopes | 1 | 2015 | 76 | 0.130 |
Why?
|
Bayes Theorem | 1 | 2022 | 2272 | 0.120 |
Why?
|
Rotation | 2 | 2010 | 510 | 0.120 |
Why?
|
Radiation Tolerance | 3 | 2014 | 476 | 0.110 |
Why?
|
Radiosurgery | 4 | 2015 | 1331 | 0.110 |
Why?
|
Scintillation Counting | 1 | 2013 | 35 | 0.110 |
Why?
|
Retrospective Studies | 7 | 2022 | 78297 | 0.110 |
Why?
|
Patient Care Planning | 1 | 1999 | 905 | 0.110 |
Why?
|
Equipment Design | 4 | 2013 | 3509 | 0.110 |
Why?
|
Cholangiocarcinoma | 1 | 2018 | 542 | 0.100 |
Why?
|
Cancer Care Facilities | 1 | 2015 | 417 | 0.100 |
Why?
|
Stereotaxic Techniques | 5 | 2002 | 540 | 0.100 |
Why?
|
Gamma Rays | 1 | 2013 | 314 | 0.100 |
Why?
|
Quality Control | 3 | 2006 | 819 | 0.100 |
Why?
|
Artifacts | 3 | 2007 | 1873 | 0.100 |
Why?
|
Male | 32 | 2024 | 351093 | 0.100 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2016 | 460 | 0.100 |
Why?
|
X-Rays | 3 | 2002 | 301 | 0.100 |
Why?
|
Forecasting | 3 | 2013 | 2905 | 0.100 |
Why?
|
Models, Organizational | 1 | 2015 | 551 | 0.100 |
Why?
|
Hospitals, General | 1 | 2015 | 761 | 0.100 |
Why?
|
Chondrosarcoma | 1 | 2013 | 288 | 0.090 |
Why?
|
Risk | 1 | 2023 | 9520 | 0.090 |
Why?
|
Clinical Protocols | 1 | 2016 | 1428 | 0.090 |
Why?
|
Rectum | 5 | 2007 | 898 | 0.090 |
Why?
|
Esophagus | 1 | 2016 | 1014 | 0.090 |
Why?
|
Swine | 3 | 2024 | 5869 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9170 | 0.080 |
Why?
|
Cyclotrons | 1 | 2008 | 30 | 0.080 |
Why?
|
Neutrophils | 1 | 2021 | 3706 | 0.080 |
Why?
|
Attitude | 1 | 2013 | 769 | 0.080 |
Why?
|
International Cooperation | 1 | 2015 | 1416 | 0.080 |
Why?
|
Thigh | 2 | 2022 | 237 | 0.080 |
Why?
|
Stochastic Processes | 1 | 2009 | 351 | 0.080 |
Why?
|
Medical Informatics | 1 | 2015 | 728 | 0.070 |
Why?
|
Carbon Isotopes | 1 | 2008 | 460 | 0.070 |
Why?
|
Water | 4 | 2022 | 1395 | 0.070 |
Why?
|
Hemangiopericytoma | 1 | 2007 | 72 | 0.070 |
Why?
|
Lung | 6 | 2024 | 9842 | 0.070 |
Why?
|
Fourier Analysis | 1 | 2008 | 433 | 0.070 |
Why?
|
Eye Neoplasms | 3 | 2011 | 307 | 0.070 |
Why?
|
Diagnostic Imaging | 1 | 2001 | 3494 | 0.070 |
Why?
|
Tomography | 1 | 2008 | 405 | 0.070 |
Why?
|
Plastics | 1 | 2007 | 114 | 0.070 |
Why?
|
Information Dissemination | 1 | 2015 | 1113 | 0.070 |
Why?
|
Research | 1 | 2015 | 1951 | 0.070 |
Why?
|
Risk Assessment | 3 | 2017 | 23453 | 0.070 |
Why?
|
Insurance Coverage | 1 | 2017 | 1910 | 0.070 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2018 | 2254 | 0.060 |
Why?
|
Computing Methodologies | 1 | 2005 | 17 | 0.060 |
Why?
|
Filtration | 1 | 2006 | 230 | 0.060 |
Why?
|
Nasopharyngeal Neoplasms | 2 | 2011 | 286 | 0.060 |
Why?
|
Insurance, Health | 1 | 2017 | 2472 | 0.060 |
Why?
|
Mediastinal Neoplasms | 2 | 1999 | 402 | 0.060 |
Why?
|
Ependymoma | 1 | 2008 | 319 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2007 | 1768 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5458 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2017 | 3543 | 0.060 |
Why?
|
Safety | 1 | 2009 | 1146 | 0.060 |
Why?
|
Biotechnology | 1 | 2006 | 279 | 0.060 |
Why?
|
Consensus | 2 | 2023 | 3011 | 0.060 |
Why?
|
Motivation | 1 | 2013 | 1963 | 0.060 |
Why?
|
Female | 13 | 2024 | 382109 | 0.050 |
Why?
|
Ions | 1 | 2003 | 261 | 0.050 |
Why?
|
Ethmoid Sinus | 1 | 2002 | 58 | 0.050 |
Why?
|
Massachusetts | 1 | 2015 | 8593 | 0.050 |
Why?
|
Internet | 1 | 2015 | 3037 | 0.050 |
Why?
|
Equipment Failure Analysis | 1 | 2005 | 847 | 0.050 |
Why?
|
Internship and Residency | 1 | 2022 | 5762 | 0.050 |
Why?
|
Metals | 1 | 2007 | 708 | 0.050 |
Why?
|
Immunotherapy | 1 | 2018 | 4594 | 0.050 |
Why?
|
Benchmarking | 1 | 2008 | 1028 | 0.050 |
Why?
|
Esophageal Neoplasms | 1 | 2011 | 1617 | 0.050 |
Why?
|
Radiography | 4 | 2012 | 6939 | 0.050 |
Why?
|
Brain Stem | 2 | 2012 | 853 | 0.050 |
Why?
|
Brain | 2 | 2024 | 26596 | 0.050 |
Why?
|
Spectrum Analysis | 1 | 2022 | 450 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10018 | 0.050 |
Why?
|
Spinal Cord | 2 | 2007 | 1773 | 0.050 |
Why?
|
Adenocarcinoma | 4 | 2003 | 6298 | 0.050 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2002 | 241 | 0.040 |
Why?
|
Medicine | 1 | 2008 | 930 | 0.040 |
Why?
|
Meningioma | 2 | 2007 | 1203 | 0.040 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 4861 | 0.040 |
Why?
|
Carbon | 1 | 2003 | 672 | 0.040 |
Why?
|
Electronics | 1 | 2001 | 319 | 0.040 |
Why?
|
Reference Standards | 1 | 2003 | 1001 | 0.040 |
Why?
|
Aged | 8 | 2018 | 164236 | 0.040 |
Why?
|
Statistics as Topic | 1 | 2006 | 2339 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4531 | 0.040 |
Why?
|
Online Systems | 1 | 2020 | 180 | 0.040 |
Why?
|
Accreditation | 1 | 2022 | 464 | 0.040 |
Why?
|
Biomedical Research | 1 | 2015 | 3327 | 0.040 |
Why?
|
Adult | 6 | 2018 | 214958 | 0.040 |
Why?
|
Middle Aged | 14 | 2018 | 214412 | 0.040 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2018 | 50 | 0.040 |
Why?
|
Computer Systems | 2 | 2008 | 471 | 0.040 |
Why?
|
Pleural Neoplasms | 1 | 2003 | 621 | 0.040 |
Why?
|
Artificial Intelligence | 2 | 2023 | 2372 | 0.040 |
Why?
|
User-Computer Interface | 2 | 2008 | 1404 | 0.040 |
Why?
|
Health Facilities | 1 | 2022 | 566 | 0.040 |
Why?
|
Health Care Sector | 1 | 2019 | 195 | 0.040 |
Why?
|
Mesothelioma | 1 | 2003 | 826 | 0.040 |
Why?
|
Lymphocyte Subsets | 1 | 2018 | 309 | 0.040 |
Why?
|
Head | 2 | 1993 | 898 | 0.040 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 294 | 0.040 |
Why?
|
Choroid Neoplasms | 1 | 1998 | 177 | 0.040 |
Why?
|
Societies, Medical | 1 | 2008 | 3789 | 0.030 |
Why?
|
Neurilemmoma | 2 | 1999 | 523 | 0.030 |
Why?
|
Animals | 6 | 2024 | 166331 | 0.030 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 1997 | 138 | 0.030 |
Why?
|
Tomography, Emission-Computed | 1 | 1999 | 1132 | 0.030 |
Why?
|
Dogs | 1 | 2020 | 3820 | 0.030 |
Why?
|
Prostate | 2 | 2022 | 1782 | 0.030 |
Why?
|
Quality of Health Care | 1 | 2011 | 4265 | 0.030 |
Why?
|
Workflow | 1 | 2020 | 835 | 0.030 |
Why?
|
Biochemical Phenomena | 1 | 2015 | 57 | 0.030 |
Why?
|
Urinary Bladder | 2 | 2007 | 1168 | 0.030 |
Why?
|
Bile Duct Neoplasms | 1 | 2000 | 595 | 0.030 |
Why?
|
Mathematical Computing | 1 | 1994 | 143 | 0.030 |
Why?
|
Cranial Irradiation | 1 | 1997 | 393 | 0.030 |
Why?
|
Background Radiation | 1 | 2013 | 2 | 0.030 |
Why?
|
Combined Modality Therapy | 3 | 2019 | 8511 | 0.030 |
Why?
|
Commerce | 1 | 2019 | 588 | 0.030 |
Why?
|
Treatment Outcome | 4 | 2018 | 63661 | 0.030 |
Why?
|
Permeability | 1 | 2015 | 724 | 0.030 |
Why?
|
Models, Structural | 1 | 1993 | 342 | 0.030 |
Why?
|
Splenic Neoplasms | 1 | 2003 | 96 | 0.030 |
Why?
|
Prostatectomy | 1 | 2021 | 1905 | 0.030 |
Why?
|
Automation | 1 | 2014 | 579 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2022 | 2767 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2022 | 2288 | 0.020 |
Why?
|
Pelvis | 1 | 1994 | 730 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2170 | 0.020 |
Why?
|
Rectal Neoplasms | 1 | 1998 | 1165 | 0.020 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2011 | 252 | 0.020 |
Why?
|
Abdominal Neoplasms | 1 | 2010 | 286 | 0.020 |
Why?
|
Rabbits | 1 | 2015 | 4783 | 0.020 |
Why?
|
Anatomy, Regional | 1 | 2007 | 4 | 0.020 |
Why?
|
Sacrum | 1 | 2010 | 276 | 0.020 |
Why?
|
Work Simplification | 1 | 2007 | 8 | 0.020 |
Why?
|
Aged, 80 and over | 4 | 2018 | 57557 | 0.020 |
Why?
|
Pilot Projects | 2 | 2017 | 8370 | 0.020 |
Why?
|
Young Adult | 2 | 2013 | 57106 | 0.020 |
Why?
|
Skull | 1 | 2012 | 808 | 0.020 |
Why?
|
Neck | 1 | 1992 | 703 | 0.020 |
Why?
|
Curriculum | 1 | 2020 | 3621 | 0.020 |
Why?
|
Organ Specificity | 2 | 2003 | 1949 | 0.020 |
Why?
|
Models, Chemical | 1 | 2008 | 614 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2018 | 4296 | 0.020 |
Why?
|
Numerical Analysis, Computer-Assisted | 1 | 2005 | 118 | 0.020 |
Why?
|
Surface Properties | 1 | 2008 | 1154 | 0.020 |
Why?
|
Neoplasm Staging | 3 | 2007 | 11064 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2018 | 4515 | 0.010 |
Why?
|
Sample Size | 1 | 2007 | 832 | 0.010 |
Why?
|
Systems Integration | 1 | 2006 | 428 | 0.010 |
Why?
|
Maximum Allowable Concentration | 1 | 2003 | 62 | 0.010 |
Why?
|
Adolescent | 2 | 2010 | 86202 | 0.010 |
Why?
|
Follow-Up Studies | 3 | 2018 | 38752 | 0.010 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2006 | 550 | 0.010 |
Why?
|
Treatment Failure | 1 | 2008 | 2614 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2003 | 3984 | 0.010 |
Why?
|
Physical Phenomena | 1 | 1999 | 47 | 0.010 |
Why?
|
United States | 2 | 2022 | 70383 | 0.010 |
Why?
|
Neoplasms, Second Primary | 1 | 2006 | 1053 | 0.010 |
Why?
|
Vascular Neoplasms | 1 | 2000 | 170 | 0.010 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2002 | 606 | 0.010 |
Why?
|
Microcomputers | 1 | 1998 | 141 | 0.010 |
Why?
|
Fluorouracil | 1 | 2002 | 1598 | 0.010 |
Why?
|
Vena Cava, Inferior | 1 | 2000 | 451 | 0.010 |
Why?
|
Cisplatin | 1 | 2002 | 1637 | 0.010 |
Why?
|
Fundus Oculi | 1 | 1997 | 532 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2002 | 2918 | 0.010 |
Why?
|
Child, Preschool | 3 | 2008 | 41376 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2000 | 3584 | 0.010 |
Why?
|
Fluorescein Angiography | 1 | 1997 | 1019 | 0.010 |
Why?
|
Prospective Studies | 1 | 2016 | 53218 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2002 | 3448 | 0.010 |
Why?
|
Infant | 2 | 2008 | 35444 | 0.010 |
Why?
|
Child | 3 | 2008 | 78456 | 0.000 |
Why?
|
Posture | 1 | 1992 | 949 | 0.000 |
Why?
|
Kidney | 1 | 2000 | 6982 | 0.000 |
Why?
|
Liver | 1 | 2000 | 7370 | 0.000 |
Why?
|
Pneumonia | 1 | 1994 | 2110 | 0.000 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 11539 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 2002 | 13538 | 0.000 |
Why?
|
Risk Factors | 1 | 2003 | 72416 | 0.000 |
Why?
|